·   Log in

Archive for March 23rd, 2010

Breast cancer vaccine Stimuvax by Merck could lead to brain infection; trials suspended

Tuesday, March 23, 2010 22:15

Clinical studies on Stimuvax (BLP25 liposome vaccine) intended to stimulate immune response in breast cancer has been suspended following brain infection in trial patients.

This was posted under category: Clinical Trials  |  Read Full Story  |  0 Comments
Tagged with: ,

Rotavirus diarrhea vaccine Rotarix by GSK may contain pig virus, warns US FDA

Tuesday, March 23, 2010 21:05

Rotarix, a vaccine to fight rotavirus infection in children marketed by GlaxoSmithKline, may contain a pig virus, warned the U.S. Food and Drug Administration.

This was posted under category: health  |  Read Full Story  |  1 Comment

Piramal Healthcare to promote oral contraceptive i-pill

Tuesday, March 23, 2010 16:32

India's Piramal Healthcare has bought the rights for the leading emergency contraceptive drug brand, i-pill, marketed by Cipla for a consideration of 950 million rupees ($21 million), reports said.

This was posted under category: Industry  |  Read Full Story  |  0 Comments

Clinical trial deaths increasing in India: Reports

Tuesday, March 23, 2010 11:29

Deaths during clinical trials are increasing in India in the recent years even as the country emerges to be one of the most sought-after destinations of human studies of experimental medicines.

This was posted under category: Clinical Trials, Featured  |  Read Full Story  |  1 Comment
Tagged with:

Lupin’s generic eszopiclone (Lunesta) may be approved to treat sleeplessness in US

Tuesday, March 23, 2010 6:38

Indian generic firm Lupin Ltd has received a tentative approval eszopiclone pills to treat sleeplessness from US FDA.

This was posted under category: Industry  |  Read Full Story  |  0 Comments
Tagged with: , ,

17 emerging markets including India to contribute nearly half of global pharma industry growth by 2013: IMS Health

Tuesday, March 23, 2010 6:06

17 high-growth pharmaceutical markets including India are expected to contribute nearly half of the annual market growth of global pharmaceutical industry in next three years, according to a new study report by IMS Health.

This was posted under category: Industry  |  Read Full Story  |  0 Comments
Tagged with: , ,

BIM 23A760 to treat gigantism is undergoing safety studies in humans: Ipsen

Tuesday, March 23, 2010 5:33

BIM 23A760, an investigational drug to treat gigantism (acromegaly) by Ipsen, is currently passing through a crucial phase of clinical testing to evaluate its safety in humans.

This was posted under category: Clinical Trials  |  Read Full Story  |  0 Comments
Tagged with: ,